QuidelOrtho Declares that its Molecular Diagnostics Approach will be Refocused

QuidelOrtho Corporation (NASDAQ:QDEL) has announced a strategic pivot in its molecular diagnostics business, seeking to acquire full ownership of LEX Diagnostics following projected 510(k) FDA clearance in late 2025 or early 2026.

QuidelOrtho declares that its molecular diagnostics approach will be refocused

A scientist observing the results of a molecular diagnostic test.

At the same time, QuidelOrtho Corporation (NASDAQ:QDEL) will stop working on its Savanna platform because of the findings of clinical trials and market factors. The business will hold a conference call to go over these updates and reiterate its full-year 2025 financial outlook.

QuidelOrtho Corporation (NASDAQ:QDEL), a global pioneer in in vitro diagnostic technology, made an initial investment in LEX Diagnostics in December 2023, gaining an exclusive option to acquire the company upon FDA certification. The ultra-fast molecular platform from LEX Diagnostics integrates PCR-level sensitivity into decentralized settings, providing multiplex testing for COVID-19, Flu A, and Flu B with results in roughly six to ten minutes.

CEO Brian J. Blaser highlighted the market alignment and performance advantages of LEX over the Savanna platform. Following the results of recent clinical trials (Savanna RVP4X), the decision to suspend Savanna development reflects a focus on speeding expansion in point-of-care molecular diagnostics, a rapidly developing diagnostics segment.

While we acknowledge the potential of QDEL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QDEL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.